EQS-Adhoc: Polyphor AG: Polyphor to present full-year 2020 financial results on March 5
Polyphor to present full-year 2020 financial results on March 5
26-Feb-2021 / 07:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Allschwil, Switzerland, February 26, 2021
Polyphor to Present Full-Year 2020 Financial Results on March 5
Polyphor AG (SIX: POLN) announced today that it will publish its full-year financial results for 2020 on March 5 at 7:30am CET.
Gökhan Batur (CEO) and Hernan Levett (CFO) will host an earnings call at 2:00pm CET, together with Frank Weber (CMDO), Daniel Obrecht (CSO) and Johann Zimmermann (Head of Oncology Research). To access the earnings call, please use the following details:
Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company's Global NK and T cell Clinical Programs yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Second Virtual Forum to Address Racial Disparities in Breast Cancer Survivorship
Community Engagement will be the Focus of Webinar on February 24, 2021
News provided by
Share this article
Share this article
ATLANTA, Feb. 18, 2021 /PRNewswire/ The Atlanta-based nonprofit TurningPoint Breast Cancer Rehabilitation will host a second virtual national forum addressing the subject of Racial Disparities in Breast Cancer Survivorship on Wednesday, February 24th, from 7 – 8:30 p.m. ET.
The second virtual forum addressing Racial Disparities in Breast Cancer Survivorship will take place on Wednesday, February 24, from 7-8:30 p.m. ET. The nonprofit organization TurningPoint Breast Cancer Rehabilitation will host the event, and Dr. Lisa VanHoose, PT, will serve as moderator. The event s focus will be on community engagement.
26
Data Bridge Market Research has recently added a new research report to its mega database of research international studies. The research report, titled “PDX Models Market 2021” identifies and analyses the emerging trends along with major drivers, challenges market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels and opportunities in the market for PDX Models industry. For a thriving business, it is quite essential to get know how of consumer’s demands, preferences, attitudes and their changing tastes about the specific product and this report is right there to solve this purpose. Furthermore, businesses can utilize the information included in this report to decide on their production and marketing strategies. A reliable global PDX Models report is structured with the vigilant efforts of innovative, enthusiastic, knowledgeable and experienced team of analysts, researchers, industry exp
Daiichi Sankyo Company, Limited: Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
ii
80% (n=64)
CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response
i Includes patients with =1 postbaseline scan or who discontinued treatment.
ii ORR is CR+PR; Responses are confirmed (CRs/PRs; n=32) plus those CRs/PRs too early to be confirmed (n=5).
iii DCR is CR+PR+SD
iv Preliminary PFS limited by earlier censoring by data cutoff due to immature duration of follow-up for 4 and 6 mg/kg dose cohorts.